Hussman Strategic Advisors Inc. Has $1.36 Million Holdings in GeneDx Holdings Corp. $WGS

Hussman Strategic Advisors Inc. decreased its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 40.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,600 shares of the company’s stock after selling 8,400 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in GeneDx were worth $1,358,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of WGS. AlphaQuest LLC increased its position in shares of GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after buying an additional 594 shares during the period. State of Alaska Department of Revenue bought a new stake in GeneDx during the third quarter valued at $187,000. Tower Research Capital LLC TRC grew its holdings in GeneDx by 479.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,818 shares of the company’s stock worth $168,000 after acquiring an additional 1,504 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of GeneDx by 61.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,917 shares of the company’s stock worth $177,000 after acquiring an additional 726 shares in the last quarter. Finally, Silver Oak Securities Incorporated bought a new position in shares of GeneDx in the 3rd quarter worth about $235,000. 61.72% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on WGS shares. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 2nd. BTIG Research boosted their target price on shares of GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Finally, Wells Fargo & Company set a $155.00 price target on shares of GeneDx and gave the company an “equal weight” rating in a research note on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, GeneDx presently has a consensus rating of “Moderate Buy” and an average price target of $138.13.

GeneDx Price Performance

Shares of WGS opened at $95.29 on Thursday. The business’s fifty day moving average is $135.44 and its 200 day moving average is $124.36. GeneDx Holdings Corp. has a 12-month low of $55.17 and a 12-month high of $170.87. The company has a quick ratio of 2.59, a current ratio of 2.71 and a debt-to-equity ratio of 0.18. The stock has a market cap of $2.75 billion, a P/E ratio of 1,058.78 and a beta of 2.01.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. The business had revenue of $116.74 million during the quarter, compared to analyst estimates of $104.33 million. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Kevin Feeley sold 3,855 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $143.87, for a total transaction of $554,618.85. Following the completion of the sale, the chief financial officer directly owned 8,731 shares of the company’s stock, valued at $1,256,128.97. The trade was a 30.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joshua Ruch sold 38,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $160.37, for a total transaction of $6,094,060.00. Following the completion of the sale, the director owned 11,941 shares in the company, valued at $1,914,978.17. This represents a 76.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 57,617 shares of company stock worth $8,992,161 over the last three months. 29.60% of the stock is currently owned by insiders.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.